Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
DFM7X6
|
|||
| Drug Name |
BEY2153
|
|||
| Indication | Alzheimer disease [ICD-11: 8A20; ICD-10: G30, G30.9; ICD-9: 331] | Phase 1 | [1] | |
| Company |
BeyondBio
|
|||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | ClinicalTrials.gov (NCT04476303) A Randomized, Double-blind, Placebo-controlled, Single and Multiple Ascending Dose Phase I Clinical Trial to Evaluate the Safety, Tolerability and Pharmacokinetics of BEY2153 After Oral Administration in Healthy Young and Elderly Male Volunteers. U.S.National Institutes of Health. | |||
| REF 2 | Clinical pipeline report, company report or official report of BeyondBio | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.